Market news

Fresh funding from the Gates Foundation for AN2 Therapeutics’ tuberculosis collaboration with GSK (LSE:GSK) has put the pharma group’s boron based LeuRS inhibitor program back in focus for investors. The GSK share price has softened in the very short term, with a 1-day share price return of a 0.22% decline and a 7-day share price return of a 2.62% decline, even as fresh R&D headlines such as the Gates backed TB work and recent conference appearances keep the pipeline in view. Yet momentum...

Detailed price information for Sanofi-Aventis S.A. ADR (SNY-Q) from The Globe and Mail including charting and trades.

GSK plc (NYSE:GSK) has spent much of 2026 adding new drugs to its pipeline, and Berenberg is starting to think investors aren’t giving it enough credit. Berenberg analyst Kerry Holford upgraded GSK from Hold to Buy and raised the firm’s price target to 2,200p from 2,000p on September 15. Berenberg said it is “increasingly optimistic” […]

GSK plc (NYSE:GSK) is adding another cancer drug to a pipeline that has been getting considerably more attention under CEO Luke Miels. The company has agreed to acquire full global rights to a trispecific T-cell engager from China-based Chimagen Biosciences in a deal worth up to $750 million. GSK (NYSE:GSK) plans to develop the experimental […]

On September 3, HUTCHMED (China) Limited (NASDAQ:HCM) announced an exclusive global development and licensing agreement with GSK plc (NYSE:GSK) for HMPL-A830, targeting colorectal, pancreatic, and lung cancers. Under the agreement, HUTCHMED receives a $110 million upfront payment, potential milestone payments up to $1.3 billion, and tiered royalties on net sales, while granting GSK worldwide rights […]

GSK (NYSE:GSK) Chief Financial Officer Julie Brown outlined the company’s growth strategy, launch priorities and cost-savings plans during a discussion with Bank of America analyst Sachin Jain following the company’s recent capital markets day. Brown said GSK’s strategic portfolio review identified

GSK Canada announced today that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA), resulting in a Letter of Intent (LOI) for Blenrep (belantamab mafodotin for injection) for the treatment of adult patients with relapsed or refractory multiple myeloma.

GSK has delivered a solid multi year share price run, helped by fresh moves in oncology and vaccines, and that raises a simple question for investors who care about valuation. Is the current price you see on screen today adequately supported by the earnings power of the business? Over the past 5 years GSK shares have returned 58.4%, which puts real weight on whether the current earnings justify where the stock now trades. Recent deals in cancer therapies, including new T cell engager and...

Tipranks Press Release.

GSK (LSE:GSK) agreed to acquire Chimagen's trispecific T cell-engager candidate for multiple myeloma, expanding its blood cancer research portfolio. The drug asset is described by the parties as a potential best in class trispecific T cell therapy targeting multiple myeloma. GSK plans to close its German vaccine manufacturing site and consolidate production in Canada, with associated job reductions and supply chain changes. The acquisition of Chimagen's trispecific T cell-engager and the...

GSK (NYSE:GSK) is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung cancer, gastrointestinal cancers and prostate cancer, with a combination of internal research and business development, according to Hesham Abdullah, the company’s senior vice pre

The acquisition is the latest in a string of major licensing deals involving Chinese biotechnology firms.

GSK's $750M Chimagen deal adds a trispecific TCE to its multiple myeloma portfolio, targeting two tumor antigens simultaneously.

GSK plc (NYSE:GSK) plans to close its vaccine manufacturing facility in Dresden, Germany, by summer 2027, putting 641 jobs at risk. The decision reflects declining demand for traditional egg-based flu vaccines, which has left GSK with more manufacturing capacity than it needs. GSK reviewed its Dresden and Ste-Foy, Canada, flu vaccine sites and chose to […]

Berenberg upgrades GSK to Buy, raises target to £22, cites pipeline catalysts and cost cuts supporting margins and growth. Read more here.

GSK (GSK) agreed to acquire global rights to an experimental T-cell engager therapy for multiple mye

GSK (LSE:GSK) was upgraded to “buy” from “hold” by Berenberg, with the broker raising its price target to £22 from £20 following an assessment of the drugmaker’s pipeline and recent business-development activity. GSK shares were up 0.

GSK PLC (LSE:GSK, NYSE:GSK) has agreed to pay up to $750 million for an experimental cancer therapy from the privately owned Chinese biotech Chimagen Biosciences. The pharmaceuticals group will hand over an undisclosed upfront fee to secure full global rights to the programme. Chimagen...

The UK's blue-chip FTSE 100 closed 0.40% higher on Monday as investors looked ahead to the Bank of E

GSK's Jideytro delivers strong first-line NSCLC results, with high response rates and durable disease control supporting a planned FDA filing.

GSK (LSE:GSK) shares rose 2. 5% to 1,815 pence on Monday after the pharmaceutical company reported results from clinical trials of two lung cancer treatments.

The British pharma company presents more positive data for Jideytro, which could become a first-line treatment for certain lung tumours

GSK plc (NYSE:GSK) is advancing its experimental seasonal influenza vaccine into late-stage development after encouraging mid-stage results in both younger and older adults. The mRNA-based candidate generated stronger immune responses than currently approved standard- and high-dose flu vaccines, according to GSK (NYSE:GSK). Its design also targets two important surface proteins on the influenza virus rather […]

Vaccine production in Dresden is set to end after 115 years, with pharmaceutical group GlaxoSmithKline (GSK) announcing plans on Thursday to close its site in the eastern German city by mid-2028. A company spokesman said production of flu vaccines would be consolidated in future at GSK's site in Ste-Foy, Canada.

Detailed price information for Merck & Company (MRK-N) from The Globe and Mail including charting and trades.

GSK plc (NYSE:GSK) has reached two important regulatory milestones involving treatments for chronic hepatitis B and rectal cancer. Bepirovirsen, which is now branded as Hibsago, was approved by Japan, marking the drug’s first authorization anywhere in the world. In a separate development, the FDA granted priority review to an application seeking approval of GSK’s (NYSE:GSK) […]

GSK PLC's (LSE:GSK, NYSE:GSK) experimental mRNA flu vaccine produced data that closely resemble Moderna's own candidate, according to Deutsche Bank. Analyst Emmanuel Papadakis reviewed detailed phase II results GSK presented at the OPTIONS XIII Conference for the Control of Influenza last...